GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing

GeoVax Labs, Inc.

Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).
Cash $5.5M at Dec 31, 2024, down from $6.5M; R&D expense $23.7M (up from $20.7M) on trial manufacturing.
BARDA $400M award supports 10,000-patient Phase 2b trial of GEO-CM04S1; manufacturing and sites confirmed.
DSMB cleared experimental arm of Phase 2 CLL trial after mRNA control arm failed primary endpoint.
Phase 2 booster data for GEO-CM04S1 in healthy adults expected H1 2025; GEO-MVA clinical eval expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.